TherapeuticsMD, Inc.

Good afternoon, ladies and gentlemen. Thank you for joining us for TherapeuticsMD's first quarter 2022 financial results conference call. I will now turn the call over to Investor Relations for TherapeuticMD's Lisa Wilson. You may begin.

Thank you, Operator. Good afternoon, everyone. and thank you for joining today to discuss our first quarter financial results and business update. This afternoon, TherapeuticsMD issued a press release announcing its first quarter 2022 financial results. The press release and accompanying presentation are available on the company's website, TherapeuticsMD, in the Investors and Media section. On today's call from TherapeuticsMD are Chief Executive Officer Hugh O'Dowd, Interim Chief Financial Officer Michael Donegan, and Chief Commercial Officer Mark Glickman. I would like to remind everyone that certain statements made during this conference call may be forward-looking statements. Such forward-looking statements are based upon current expectations and there can be no assurance that the results contemplated in these statements will be realized. Actual results may differ materially from such statements due to a number of factors of risks, some of which are identified in our press release, and are annual, quarterly, and other reports filed with the SEC. These forward-looking statements are based upon information available to TherapeuticsMD today and the company assumes no obligation to update these statements as circumstances change. An audio recording and webcast replay for today's conference call will also be available online in the Investors and Media section of the company's website. For the benefit of those who may be listening to the replay or archived webcast, this call was held and recorded on May 16, 2022. With that, I'll turn the call over to TherapeuticMD's CEO, Hugh O'Dell.

Thank you, Lisa, and thank you, everyone, for joining our call today. Last quarter, we reviewed our 2022 priorities, including details surrounding our Antivira manufacturing supply challenges, and today, I'd like to share our progress against our goals, including key milestones, met in the first quarter of 2022. Our net product revenue for the first quarter was $19.3 million, compared to net product revenue of $18.7 million in the fourth quarter of 2021. As we discussed last quarter, our first quarter revenue performance was impacted by Antivirus manufacturing and supply challenges. As also previously communicated, We believe that our antivirus supply challenges peaked in the first quarter of 2022, and we envision incremental improvement as the year progresses. Turning to our recent $150 million VitaCare divestiture, I am quite pleased that our organization drove a rapid and successful deal conclusion just five weeks following its announcement. And finally, With regard to our pathway to achieving EBITDA break-even, we shall pause offering 2022 full-year guidance until we can provide clarity regarding our capital structure, as well as receive feedback from the FDA on our pending manufacturing supplement. And with that, I'll turn it over to our Interim Chief Financial Officer, Michael Donegan, to discuss our financial results in greater detail. Michael?